Abstract: A method according to the present disclosure improves sleep states, maintains a sound sleep, restores the balance of gut microbiota disrupted by sleep disorders, and supports the management of health including metabolic syndrome. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Limosilactobacillus reuteri LM1063 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Mar. 23, 2017, under the Accession Number: KCTC 13232BP.

Abstract: Mixed strains composition capable of improving whey protein proteolysis and lactose intolerance, and more particularly mixed strains composition of Limosilactobacillus reuteri LM1071 (Accession Number: KCCM12650P) and Lactobacillus gasseri LM1065 (Accession Number: KCCM13018P), which is capable of degrading whey protein to branched chain amino acid (BCAA), arginine, and phenylalanine and improving lactose intolerance is proposed. A composition including mixed strains of Limosilactobacillus reuteri LM1071 (Accession Number: KCCM12650P) and Lactobacillus gasseri LM1065 (Accession Number: KCCM13018P) has excellent protein proteolysis and thus can produce BCAA (valine, leucine and isoleucine), arginine, and phenylalanine, which are helpful in forming muscles and suppressing muscle loss, by degrading whey proteins, and has excellent ?-galactosidase activity and thus can hydrolyze lactose.

Abstract: A mixed strain of probiotics having immunoregulatory functions and a composition comprising the same are provided. The composition can regulate immunity by increasing the production amount of NO or inhibiting the excessive production of NO induced by an inflammatory substance. The mixed strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions, and the like.

Abstract: The present disclosure relates to an immune-enhancing composition comprising Lactobacillus rhamnosus LM1019 and starter strains. An immune-enhancing composition comprising Lactobacillus rhamnosus LM1019 and starter strains according to the present disclosure has an excellent immune-enhancing effect by increasing the amount of nitric oxide (NO) produced and improving the TNF-? secretion ability. Also, since the immune-enhancing composition contains the starter strain, it can be used to produce fermented milk. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Lactobacillus rhamnosus LM1019 strain was deposited with the international depositary authority: the Korean Culture Center of Microorganisms (KCCM) on Aug. 11, 2017, under the Accession Number: KCCM12308P.

Abstract: The present disclosure relates to a strain of Lactobacillus gasseri LM1065 (KCCM13018P) and a composition of relieving premenstrual syndrome containing the strain. A strain of Lactobacillus gasseri LM1065 (KCCM13018P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO in blood and TL-6 gene expression and increasing the production ratio of prostaglandin E1/prostaglandin E2 in blood and DGLA levels. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions, and the like.

Abstract: The present disclosure relates to a method for preparing killed lactic acid bacteria using a bioreactor including a culture device and a membrane filter, and to killed lactic acid bacteria prepared by the preparation method.

Abstract: The present disclosure relates to a strain of Lactobacillus reuteri LM1071 (KCCM12650P) and a composition for relieving menstrual pain, comprising the same. A strain of Lactobacillus reuteri LM1071 (KCCM12650P) according to an embodiment of the present disclosure can relieve premenstrual syndrome by reducing NO, prostaglandin E2 and leukotriene in blood and increasing epoxyeicosatrienoic acid (EET) and the production ratio of prostaglandin E1/prostaglandin E2. Therefore, the strain can be applied to food compositions, health functional food compositions, pharmaceutical compositions and the like.

Abstract: The present disclosure relates to a method for preparing killed lactic acid bacteria using a bioreactor including a culture device and a membrane filter, and to killed lactic acid bacteria prepared by the preparation method.